Our drug candidate
p-HTMI is currently being developed for use during glioma brain tumor surgery for detection and illumination of glioma stem cells. Emerging research suggests that failure to target glioma stem cells rather than the inability to remove tumors through surgery, radiation, or chemotherapy, explains the poor survival of malignant glioma patients. p-HTMI is intended to enable neurosurgeons to detect, and surgically remove, glioma stem cells during fluorescence-guided surgery.
p-HTMI is currently in pre-clinical phase and is expected to enter clinical phase I during 2026. Accordingly, p-HTMI is not commercially available.
Our IVD product
GlioStem® is a CE-marked in vitro diagnostic (IVD) medical device designed for nearly instant detection of neural stem cells and stem-like cells in glioma. It is based on polymer technology and defines a new generation of biomarkers. Within a maximum of 10 minutes after administration of GlioStem®, fluorescence emission is observed without any modulation of the cells or additional reagents.
For further information, please contact us by e-mail or by filling out this form.